Other · 2013
EditorialPublished 27 Aug 2020
New Drug Update
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Neurocrine Biosciences, Inc. has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for once-daily dosing of valbenazine
Subjects
Mental Health and PsychologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Other · 2015
Drug development update
Case report · 2012
Antipsychotic Drug Development Update: Pipeline and Progress
Review article · 5 Jul 2021
Update on Non-immediate Drug Allergy Reactions: State and New Aspects
Editorial · 26 Aug 2020
New Drugs Quetiapine Sustained Release Studiedin the Treatment of Schizophrenia
More from this journal
The newest in Clinical Schizophrenia & Related Psychoses.
Article · 18 Mar 2026
Antipsychotics vs. ECT with Antipsychotics: A PANSS and SCORS Investigation in Paranoid Schizophrenia
Article · 30 Sep 2025
Successful Treatment of a Treatment Refractory Patient with Clozapine Retrial
Article · 24 Jun 2025
Check the Necessity of Performing A CT Scan of the Brain in Patients with Mild Trauma
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Schizophrenia & Related Psychoses
- SubjectMental Health and Psychology
- BylineArticles whose byline prints “Peter F. Buckley”

